MOUNTAIN VIEW, Calif., Sept. 16 /PRNewswire-FirstCall/ -- VIVUS, Inc. , announced today that it is offering to sell, subject to market and other conditions, 9,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. VIVUS also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by VIVUS. J.P. Morgan Securities Inc. is acting as sole book-running manager of the proposed offering.
Copies of the preliminary prospectus supplement and accompanying prospectus may be obtained by contacting J.P. Morgan Securities Inc., Attention: Prospectus Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling (718) 242-8002.
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products.
SOURCE VIVUS, Inc.
CONTACT: Timothy E. Morris, Chief Financial Officer of VIVUS, Inc.,
+1-650-934-5200, or Brian Korb, Investor Relations, The Trout Group,
+1-646-378-2923
